Lyra Direct SARS-CoV-2 Assay Emergency Use Authorization- Ref: M124. The Lyra Direct SARS-CoV...
FDA Device Recall #Z-2477-2021 — Class II — August 13, 2021
Recall Summary
| Recall Number | Z-2477-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 13, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Quidel Corporation |
| Location | Athens, OH |
| Product Type | Devices |
| Quantity | 81,910 kits |
Product Description
Lyra Direct SARS-CoV-2 Assay Emergency Use Authorization- Ref: M124. The Lyra Direct SARS-CoV-2 Assay is a real-time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal (NS), nasopharyngeal (NP), or oropharyngeal (OP) direct swab specimens from individuals suspected of COVID-19 by their healthcare provider
Reason for Recall
Revised Instructions for Use: Potential for specimens from patients with high SARS-CoV-2 viral loads to be falsely interpreted as negative if target amplification occurs prior to a cycle-threshold (Ct) value of 5 when using the Thermo Fisher QuantStudio 7 Pro, the Applied Biosystems 7500 Fast Dx, the Applied Biosystems 7500, the Bio-Rad CFX96 Touch", the Roche LightCycler LC 480 II/ cobas z 480, or the Qiagen Rotor-Gene¿ MDx.
Distribution Pattern
Worldwide distribution - US Nationwide distribution including Puerto Rico and the countries of Canada, Panama, Virgin Islands, Germany, Honduras.
Lot / Code Information
All lots
Other Recalls from Quidel Corporation
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2545-2025 | Class II | QuickVue: Dipstick Strep A Test: 50T, REF: 2010... | Jun 17, 2025 |
| Z-1636-2024 | Class II | QUIDEL InflammaDry MMP-9 Test, REF: PRS-ID-20-U... | Mar 5, 2024 |
| Z-1637-2024 | Class II | QUIDEL InflammaDry MMP-9 Test, REF: PRS-ID-20, ... | Mar 5, 2024 |
| Z-1086-2024 | Class II | The Sofia 2 Flu + SARS Antigen FIA employs immu... | Jan 3, 2024 |
| Z-1308-2023 | Class II | MicroVue C1-Inhibitor Plus EIA for measuring th... | Feb 1, 2023 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.